USPTO serial 88086896
CELLCHEM
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- JOHNSON, DONALD
- Law office
- TMEG LAW OFFICE 104 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with CELLCHEM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical decoctions for the treatment of cough; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention of bone loss, blood colt; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of worms in pets; Pharmaceutical preparations for the treatment of cough, cold, pain, fever, constipation, cancer, anemia, irritable bowel syndrome, hypertension, epilepsy, amoebic infection, Parkinson's disease, nausea and vomiting, fungal and yeast infections, cytomegalo virus infections, diabetes, fabry disease, hepatitis B infection, bad cholesterol, malaria, multiple selerosis gastroesophageal reflux disease, rheumatoid arthritis, tourette's disorder, bipolar disorder, obesity, opioid overdose treatment, cardiac treatment, spam pain, Ulcer treatment, idiopathic pulmonary fibrosis treatment; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, dantrolene sodium for injection; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Alcohol for pharmaceutical purposes; Alginates for pharmaceutical purposes; Almond milk for pharmaceutical purposes; Aloe vera preparations for pharmaceutical purposes; Aluminium acetate for pharmaceutical purposes; Analgesic and muscle relaxant pharmaceutical preparations; Anti-diabetic pharmaceuticals; Anti-epileptic pharmaceutical preparations; Antibacterial pharmaceuticals; Antimicrobial preparations for inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals; Antimicrobial preservatives for cosmetics and pharmaceuticals; Balms for pharmaceutical purposes; Bicarbonate of soda for pharmaceutical purposes; Bismuth preparations for pharmaceutical purposes; Bismuth subnitrate for pharmaceutical purposes; Bromine for pharmaceutical purposes; Capsules sold empty for pharmaceuticals; Cardiovascular pharmaceuticals; Cellulose esters for pharmaceutical purposes; Cellulose ethers for pharmaceutical purposes; Charcoal for pharmaceutical purposes; Collodion for pharmaceutical purposes; Cream of tartar for pharmaceutical purposes; Creosote for pharmaceutical purposes; Cytostatics for pharmaceutical purposes; Dermatological pharmaceutical products; Dextrins for pharmaceutical use; Digestives for pharmaceutical purposes; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Ethers for pharmaceutical purposes; Eucalyptus for pharmaceutical purposes; Extracts of hops for pharmaceutical purposes; Ferments for pharmaceutical purposes; Fish meal for pharmaceutical purposes; Flaxseed for pharmaceutical purposes; Flaxseed meal for pharmaceutical purposes; Flour for pharmaceutical purposes; Flowers of sulfur for pharmaceutical purposes; Frostbite salve for pharmaceutical purposes; Gelatin capsules sold empty for pharmaceuticals; Glossy ganoderma for pharmaceutical purposes; Guaiacol for pharmaceutical purposes; Hyaluronic acid for pharmaceutical purposes; Hydrated chloral for pharmaceutical purposes; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Injectable pharmaceuticals for treatment of anaphylactic reactions; Iodine for pharmaceutical purposes; Linseed meal for pharmaceutical purposes; Liquorice for pharmaceutical purposes; Malt for pharmaceutical purposes; Meal for pharmaceutical purposes; Melissa water for pharmaceutical purposes; Menthol for pharmaceutical purposes; Milk ferments for pharmaceutical purposes; Mint for pharmaceutical purposes; Myrobalan bark for pharmaceutical purposes; Ocular pharmaceuticals; Pepsins for pharmaceutical purposes; Phenol for pharmaceutical purposes; Plant extracts for pharmaceutical purposes; Plant extracts for medical, veterinary and pharmaceutical purposes; Potassium preparations for pharmaceutical purposes; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; Propolis for pharmaceutical purposes; Rhubarb roots for pharmaceutical purposes; Royal jelly for pharmaceutical purposes; Specialized tablets, capsules and powders for the delivery of pharmaceuticals sold without the pharmaceutical ingredient; Starch for pharmaceutical purposes; Stick liquorice for pharmaceutical purposes; Thymol for pharmaceutical purposes; Turpentine for pharmaceutical purposes; Unit dose capsules sold empty for pharmaceutical use; Yeast for pharmaceutical consumption; Yeast for pharmaceutical purposes; Yeast or yeast extracts for medical, veterinary or pharmaceutical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 8, 2019 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 8, 2019 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Dec 7, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 7, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 7, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 7, 2018 | DMCC | DATA MODIFICATION COMPLETED | — |
| Dec 7, 2018 | ALIE | ASSIGNED TO LIE | — |
| Dec 6, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 30, 2018 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Aug 29, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 24, 2018 | NWAP | NEW APPLICATION ENTERED | — |